392 related articles for article (PubMed ID: 26566626)
1. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
Roviello G; Polom K; Petrioli R; Marano L; Marrelli D; Paganini G; Savelli V; Generali D; De Franco L; Ravelli A; Roviello F
Tumour Biol; 2016 Jan; 37(1):127-40. PubMed ID: 26566626
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
3. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
Tirino G; Pompella L; Petrillo A; Laterza MM; Pappalardo A; Caterino M; Orditura M; Ciardiello F; Galizia G; De Vita F
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205505
[TBL] [Abstract][Full Text] [Related]
4. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
5. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors.
Argyriou AA; Kalofonos HP
Mol Med; 2009; 15(5-6):183-91. PubMed ID: 19305491
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Wong H; Yau T
Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
9. [A perspective: role of targeted therapy in colon cancer].
Chung HH; Jang BI
Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies for treating gastric cancer: promises and pitfalls.
Sibertin-Blanc C; Ciccolini J; Norguet E; Lacarelle B; Dahan L; Seitz JF
Expert Opin Biol Ther; 2016 Jun; 16(6):759-69. PubMed ID: 26971395
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal antibody therapy in breast cancer].
Dank M; Tõkés T
Magy Onkol; 2013 Sep; 57(3):157-65. PubMed ID: 24107821
[TBL] [Abstract][Full Text] [Related]
13. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C; Mulder K; Spratlin J
Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
[TBL] [Abstract][Full Text] [Related]
14. [Research status quo and progression in targeted therapy for advanced gastric cancer].
Feng R; Zhang X; Yang S
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1191-1196. PubMed ID: 27781258
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of cancer in 2012.
Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor a inhibition in gastric cancer.
Park DJ; Thomas NJ; Yoon C; Yoon SS
Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
Piront P; Van Daele D; Belaiche J; Polus M
Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
20. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]